a magnifying glass

adobe pdf icon Analogic Corporation Launches the LIFEGARD II Family of Non-Invasive Patient Monitors at the ACC in Atlanta, March 11-14

Analogic Corporation Launches the LIFEGARD II Family of Non-Invasive Patient Monitors at the ACC in Atlanta, March 11-14

Analogic Corporation Launches the LIFEGARD II Family of Non-Invasive Patient Monitors at the ACC in Atlanta, March 11-14

PEABODY, Mass.–(BUSINESS WIRE)–March 6, 2006–Analogic
Corporation (NASDAQ: ALOG) today announced the official product launch
of the LIFEGARD® II family of non-invasive patient monitors at
ACC.06 (American College of Cardiology), March 11-14, 2006, in
Atlanta, Georgia (Booth #3432).

The LIFEGARD II, the latest in a series of non-invasive patient
monitors from Analogic, is the platform upon which the Company will
expand its patient monitoring offerings. LIFEGARD II with ICG
(Impedance CardioGraphy) uses Thoracic Electrical Bioimpedance (TEB)
to measure continuous cardiac output, and is the only patient monitor
that has ICG totally integrated with all other standard, non-invasive
vital signs.

Non-invasive hemodynamic measurement is a valuable, established
tool in managing cardiac patients, and the LIFEGARD II with ICG is the
most comprehensive non-invasive cardiac output monitor available
today.

Dan Webster, General Manager of Analogic’s Life Care Systems
Division, noted, “The LIFEGARD II family represents a significant
expansion of our growing LIFEGARD family of patient monitors. The
non-invasive, portable LIFEGARD II with ICG adds a new level of
versatility to patient monitoring by allowing clinicians to more
comprehensively monitor patient hemodynamics anywhere in the hospital
or in non-acute environments such as freestanding clinics and
physicians’ offices. Clinicians can evaluate a patient in considerably
less time and with no risk of infection, compared to conventional
invasive monitoring modalities.”

Analogic’s LIFEGARD family of non-invasive patient monitors also
includes LIFEGARD, a general-purpose monitor that measures ECG, heart
rate, respiration, pulse oximetry, non-invasive blood pressure, and
temperature; LIFEGARD ICG, a non-invasive hemodynamic status monitor;
and the FETALGARD Lite® and FETALGARD Lite with NIBP, antepartum
fetal monitors capable of monitoring twins. LIFEGARD II multiparameter
monitors can also measure end-tidal CO2, in addition to ICG and the
five standard vital sign parameters. Additional models with expanded
capabilities which have already received U.S. Food & Drug
Administration (FDA) clearance will be made available over the next 12
months. For more information, visit Booth #3432 at ACC in Atlanta, go
to www.analogic.com/lifegard, or call 800-599-7769.

Analogic Corporation is a leading designer and manufacturer of
advanced health and security systems and subsystems sold primarily to
Original Equipment Manufacturers (OEMs). The Company is recognized
worldwide for advancing the state of the art in Computed Tomography
(CT), Digital Radiography (DR), Ultrasound, Magnetic Resonance Imaging
(MRI), Patient Monitoring, and Embedded Multiprocessing.

CONTACT:
Analogic Corporation
Paul M. Roberts, 978-326-4213
or
David Kutas, 978-326-4344

SOURCE:
Analogic